|
|Section2= |Section3= }} Ethyl eicosapentaenoic acid (E-EPA) marketed as Vascepa, Epadel, EPAX, is a synthetic derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA). In Japan, E-EPA is often called EPA-E. This compound has been FDA-approved for use for reduction of high triglyceride levels. E-EPA may exhibit antipsychotic and antidepressive effects,〔Horrobin D. The Madness of Adam and Eve. How schizophrenia shaped humanity. Bantam Press 2001〕 and it is therefore of special interest in psychiatry. == Cardiovascular diseases, diabetes == The Japan Eicosapentaenoic acid Lipid Intervention Study (JELIS) tested the effects of long-term use of E-EPA (1800 mg/day) in addition to a statin in Japanese patients with hypercholesterolemia. The results suggest that the addition of E-EPA to statin therapy prevents major coronary events, angina pectoris and clinical myocardial infarctions, apparently through mechanisms independent from regulation of the lipid metabolism. It has been suggested that the cardioprotective action of E-EPA is probably mediated by its anti-inflammatory properties.〔King A. Does treatment with eicosapentaenoic acid prevent major coronary events in patients with hypercholesterolemia? Editorial. Commentary by William S. Harris Nat Clin Pract Cardiovasc Med. 2007 Aug 14; (Free Full Text )〕〔 (as PDF )〕 In addition, E-EPA may improve the clinical outcome in type 2 diabetes and its cardiovascular complications, such as coronary artery disease and thickening of carotid arteries. E-EPA may on the one hand reduce the platelet-derived microparticles (PDMP) and on the other enhance the cardioprotective hormone adiponectin in hyperlipidemic, diabetic patients. According to Japanese mice studies, E-EPA may prevent and correct non-alcoholic fatty liver. In July 2012, the US Food and Drug Administration approved Amarin Corporation's prescription drug Vascepa for severe hypertriglyceridemia. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Ethyl eicosapentaenoic acid」の詳細全文を読む スポンサード リンク
|